MarkNtel Advisors recently published a detailed industry analysis of the Saudi Arabia Diabetes Drug Market. The report covers growth trends, geographical marketing strategies, challenges, opportunities, and drivers influencing the market.

Saudi Arabia Diabetes Drug Market, Share, and Trends Analysis Report – Industry Overview and Forecast to 2030

The Saudi Arabia Diabetes Drug Market size was valued at around USD 2 billion in 2024 and is projected to reach USD 3.4 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 9% during the forecast period (2025-30)

Key Findings in Saudi Arabia Diabetes Drug Market:

• Historical Analysis: 2020–2023
• Base Year: 2024
• Forecast Period: 2025–2030

Leading Market Players- Novo Nordisk A/S, Takeda, Pfizer, Eli Lilly, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, Merck and Co., AstraZeneca, Julphar, Bristol Myers Squibb, Novartis, Sanofi Aventis, and others

Key Highlights of the Report

• Market Dimensions & Projections
• Pricing Evaluation,
• Recent Strategic Moves by Companies,
• Primary Stakeholders,
• Analysis of Import and Export Trends,
• Competitive Landscape Assessment,
• Emerging Opportunities,
• Market Trends and Indicators

What are the major Driver the Saudi Arabia Diabetes Drug industry?

High Prevalence of Diabetes Propelling Market Growth – Due to genetic predispositions and unhealthy lifestyle choices, Saudi Arabia has one of the highest prevalence rates in the world. By 2026, around 24% of the total adult population of Saudi Arabia is expected to have Diabetes which was just around 17.7% in 2021. This rising prevalence is leading the nation to become the 2nd highest in the Middle East and 7th highest globally in diabetes occupancy. An unhealthy lifestyle has resulted in the prevalence of obesity-related problems in Saudi Arabia that majorly pose a threat to several chronic diseases like Type-2 diabetes. An approximate 35.4% of the adult population of Saudi Arabia suffers from obesity. This creates an immense nationwide demand for Diabetes Drugs for the treatment and prevention of diabetes, thereby significantly contributing to the market growth.

Another reason is the country has some of the highest per capita consumption of sugar-filled drinks which worsens the diabetes epidemic. High prevalence rates of the disease result from this sort of sedentary behavior allied with diets full of fat and sugar which fuels the growth of the Saudi Arabia Diabetes Drug Market.

Download now and gain valuable insights to inform your business strategy, drive growth, and stay ahead of the competition - Download Free PDF Sample- https://www.marknteladvisors.com/query/request-sample/saudi-arabia-diabetes-drug-market.html

What segments define the Saudi Arabia Diabetes Drug Market from 2025 to 2030? How do these segments contribute to market dynamics and growth?

By Insulins

• Basal- Market Size & Forecast 2020-2030, USD Million
• Lantus (Insulin Glargine)- Market Size & Forecast 2020-2030, USD Million
• Levemir (Insulin Detemir)- Market Size & Forecast 2020-2030, USD Million
• Toujeo(Insulin Glargine)- Market Size & Forecast 2020-2030, USD Million
• Tresiba(Insulin Degludec)- Market Size & Forecast 2020-2030, USD Million
• Basaglar (Insulin Glargine) - Market Size & Forecast 2020-2030, USD Million
• Bolous- Market Size & Forecast 2020-2030, USD Million
• NovoRapid/Novolog (Insulin Aspart)- Market Size & Forecast 2020-2030, USD Million
• Humalog (Insulin Lispro)- Market Size & Forecast 2020-2030, USD Million
• Apidra (Insulin Glulisine)- Market Size & Forecast 2020-2030, USD Million
• Traditional Insulins- Market Size & Forecast 2020-2030, USD Million
• Novolin/ Actrapid/Insulatard- Market Size & Forecast 2020-2030, USD Million
• Humulin- Market Size & Forecast 2020-2030, USD Million
• Insuman- Market Size & Forecast 2020-2030, USD Million
• Biosimilar Insulins- Market Size & Forecast 2020-2030, USD Million
• Insulin Glargine Biosimilars- Market Size & Forecast 2020-2030, USD Million
• Human Insulin Biosimilars- Market Size & Forecast 2020-2030, USD Million

According to report, Based on the Insulins, Basal leads the Saudi Arabia Diabetes Drugs Market. It holds approximately 43.75% share of the total market.

By Oral Anti-Diabetic Drugs

• Biguanides- Market Size & Forecast 2020-2030, USD Million
• Metformin- Market Size & Forecast 2020-2030, USD Million
• Alpha-Glucosidase Inhibitors- Market Size & Forecast 2020-2030, USD Million
• Dopamine D2 receptor agonist- Market Size & Forecast 2020-2030, USD Million
• Bromocriptin- Market Size & Forecast 2020-2030, USD Million
• SGLT-2 Inhibitors- Market Size & Forecast 2020-2030, USD Million
• Invokana (Canagliflozin)- Market Size & Forecast 2020-2030, USD Million
• Jardiance (Empagliflozin)- Market Size & Forecast 2020-2030, USD Million
• Farxiga/Forxiga (Dapagliflozin)- Market Size & Forecast 2020-2030, USD Million
• Suglat (Ipragliflozin)- Market Size & Forecast 2020-2030, USD Million
• DPP-4 Inhibitors- Market Size & Forecast 2020-2030, USD Million
• Onglyza (Saxagliptin)- Market Size & Forecast 2020-2030, USD Million
• Tradjenta (Linagliptin)- Market Size & Forecast 2020-2030, USD Million
• Vipidia/Nesina(Alogliptin)- Market Size & Forecast 2020-2030, USD Million
• Galvus (Vildagliptin)- Market Size & Forecast 2020-2030, USD Million
• Sulfonylureas- Market Size & Forecast 2020-2030, USD Million
• Meglitinides- Market Size & Forecast 2020-2030, USD Million

By Non-Insulin Injection Drugs

• GLP-1 Receptor Agonists- Market Size & Forecast 2020-2030, USD Million
• Victoza (Liraglutide)- Market Size & Forecast 2020-2030, USD Million
• Byetta (Exenatide)- Market Size & Forecast 2020-2030, USD Million
• Bydureon (Exenatide)- Market Size & Forecast 2020-2030, USD Million
• Trulicity (Dulaglutide)- Market Size & Forecast 2020-2030, USD Million
• Lyxumia (Lixisenatide)- Market Size & Forecast 2020-2030, USD Million
• Amylin Analogue- Market Size & Forecast 2020-2030, USD Million
• Symlin (Pramlintide)- Market Size & Forecast 2020-2030, USD Million

By Combination Drugs

• Insulin Combinations- Market Size & Forecast 2020-2030, USD Million
• NovoMix (Biphasic Insulin Aspart)- Market Size & Forecast 2020-2030, USD Million
• Ryzodeg (Insulin Degludec and Insulin Aspart)- Market Size & Forecast 2020-2030, USD Million
• Xultophy (Insulin Degludec and Liraglutide)- Market Size & Forecast 2020-2030, USD Million
• Oral Combinations- Market Size & Forecast 2020-2030, USD Million
• Janumet (Sitagliptin and Metformin)- Market Size & Forecast 2020-2030, USD Million

By Distribution Channel

• Hospital Pharmacies- Market Size & Forecast 2020-2030, USD Million
• Retail Pharmacies- Market Size & Forecast 2020-2030, USD Million
• Online Pharmacies- Market Size & Forecast 2020-2030, USD Million
• Clinics and Diabetes Centers- Market Size & Forecast 2020-2030, USD Million

According to report, Based on the distribution channel, Hospital Pharmacies lead the Saudi Arabia Diabetes Drugs Market. It holds approx. 40% share of the total global market.

Explore the Complete Saudi Arabia Diabetes Drug Market Analysis Report – https://www.marknteladvisors.com/research-library/saudi-arabia-diabetes-drug-market.html

Geographical Analysis: Saudi Arabia Diabetes Drug Market

 By Region

• Northern
• Central
• Southern
• Eastern
• Western

The Saudi Arabia Diabetes Drug Industry Recent Development:

• October 2024: Novo Nordisk A/S announced an agreement with Lifera. Through Lifera’s subsidiary, SaudiBio, the two companies have agreed to localize insulin production in Saudi Arabia.

• August 2024: Boehringer Ingelheim and Alpha Pharma collaborated to localize the production of one of its Type 2 Diabetes Medicines in Saudi Arabia. Alpha Pharma, aims to combat type 2 diabetes in the Kingdom and is fully aligned with the Kingdom’s Vision 2030 pillars.

Key Questions Addressed in This Study

• What are the primary factors driving the growth of the Saudi Arabia Diabetes Drug market?
• How is the Saudi Arabia Diabetes Drug market expected to evolve over the next five years?
• What key insights can be drawn from current trends shaping the market?
• What is the current market size, and how is it forecasted to change in the coming years?
• What is the future outlook for the market in terms of technological innovation and geographic expansion?

For a Customized Analysis Report, Just Drop Your Inquiry Here – https://www.marknteladvisors.com/query/request-customization/saudi-arabia-diabetes-drug-market.html

Why MarkNtel Advisors?

MarkNtel Advisors is a leading research, consulting, & data analytics firm that provides an extensive range of strategic reports on diverse industry verticals. We deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, & individuals, among others.

Our specialization in niche industries informed way and entail parameters like Go-to-Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, & trend analysis, among others, for 15 diverse industrial verticals.

More Research Studies Report:

-Biocomposites Market size was valued at around USD 36.9 billion in 2024 and is projected to reach USD 89 billion by 2030 with a CAGR of around 16%.

-Green Solvents Market size was valued at around USD 1.34 billion in 2024 & is projected to reach USD 1.87 billion by 2030 with a CAGR of around 5.7%.

For Media Inquiries, Please Contact:

Email: [email protected]

Trending Blogs : www.marknteladvisors.com/blogs

Export-import Data : https://www.marknteladvisors.com/export-import-data